Clinical Trial

Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules: A Prospective Study

Study acronym: RFAT
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2025 (before its estimated February 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
Title: Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules: A Prospective Study Purpose: The goal of this clinical trial is to learn if single-session radiofrequency ablation (RFA) can effectively reduce the volume of benign thyroid nodules in adults. It will also evaluate the safety of the RFA procedure. The main questions it aims to answer are: 1. Does RFA procedure reduce the size of thyroid nodules (measured by volume reduction rate - VRR)? 2. What medical problems or complications do participants experience after undergoing RFA? 3. How does RFA affect thyroid hormone levels (TSH, FT4)? 4. Is RFA equally effective in purely cystic nodules, solid nodules, and predominantly cystic nodules? Comparator: This is a single-arm study, so there is no placebo or comparison treatment group. All participants will undergo RFA, and the results will be assessed over time. Participants will: * Undergo one session of RFA for benign thyroid nodules. * Be followed up with clinical visits and ultrasound assessments at 1, 6, and 12 months. * Have thyroid hormone levels tested and nodule size measured by ultrasound at each follow-up. * Be monitored for any side effects or complications such as voice changes, pain, or bleeding.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-04; most recent amendment 2025-12-08.
Status change: Enrolling by Invitation → Active, Not Recruiting 2025-09-25
Trial Details
NCT Number NCT07115576
Lead Sponsor Hue University of Medicine and Pharmacy
Collaborators: Da Nang Family General Hospital
Conditions Benign Thyroid Nodules
Enrollment 106 participants
Start Date 2023-02-10
Primary Completion 2026-02-10 (estimated)
Study Completion 2026-04-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-16